FDA to broaden evaluation of opioid addiction treatments

As part of the US government’s move to pharmaceutical products for drug problems, the FDA will now consider factors such as whether a drug could reduce overdose rates or transmission of infectious diseases, rather than only whether a potential treatment reduces opioid use.